Jorge A. Goldstein (PhD)

Director and founder Sterne Kessler Goldstein Fox
Back to event


Sterne Kessler Goldstein Fox


+1 202 371 2600

A Pioneer in Biotechnology Patent Law.

Jorge is considered by his peers and clients to be one of the country’s pioneers in biotechnology patent law. In 2017, Jorge was inducted into LMG Life Sciences Hall of Fame and he was named as a finalist in their “Patent Strategy and Management Attorney of the Year- District of Columbia” category. He wrote the book U.S. Biotechnology Patent Law published in 2016, with a second edition including updates to case law published 2017. The books guides readers to understanding case law dealing with patents in biotechnology. He has almost forty years’ experience in the preparation and prosecution of patent applications before the U.S. and foreign patent offices in scientific areas such as genomics, molecular and cell biology, recombinant DNA technology, immunology, transgenics, therapeutic methods, stem cells, pharmaceuticals and more recently, BioFETs (biological field effect transistors).

A founder of the firm, Jorge is a Director in the firm’s Biotechnology Practice Group. He chairs the firm’s IP and Human Rights Pro Bono Practice, which was recognized as the winner of the 2015 Financial Times’ Most Innovative North American Lawyers award in the “Innovation in a Social Responsibility Project” category. He has handled multiple and varied interferences over many years, including successful appeals to the Court of Appeals for the Federal Circuit. He has also been involved in Inter Partes Reviews at the USPTO, as well as European oppositions, and arbitrations in District Court and in Appellate litigation both as counsel and expert witness, and in counseling clients on intellectual property strategy, trade secrets, licensing, research contracts, university-industry relations, federal licensing, due diligence, acquisitions and employment agreements. He was lead counsel in the 1988 appellate case of In re Wands et al. 8 USPQ2d 1400 (Fed. Cir.), a pivotal decision on biotechnology enablement requirements.

He has been named Visiting Professor of Law by the Universidad Austral in Buenos Aires, Argentina, where he annually teaches biotech patent law in the only WIPO-certified regional master’s IP program in Latin America.